Leerink Partnrs Brokers Decrease Earnings Estimates for AXSM

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Analysts at Leerink Partnrs reduced their FY2025 earnings per share estimates for shares of Axsome Therapeutics in a report released on Monday, February 10th. Leerink Partnrs analyst M. Goodman now anticipates that the company will earn ($4.60) per share for the year, down from their previous estimate of ($4.30). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($4.70) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics’ FY2026 earnings at ($0.40) EPS.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, beating the consensus estimate of ($1.38) by $0.04. The firm had revenue of $104.76 million during the quarter, compared to analyst estimates of $98.71 million. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. During the same quarter in the previous year, the firm earned ($1.32) earnings per share.

Several other equities research analysts have also weighed in on AXSM. Leerink Partners increased their price objective on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a research note on Monday. Robert W. Baird increased their price target on Axsome Therapeutics from $112.00 to $116.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Cantor Fitzgerald restated an “overweight” rating and set a $121.00 price objective on shares of Axsome Therapeutics in a research report on Thursday, December 12th. Needham & Company LLC reaffirmed a “buy” rating and issued a $133.00 target price on shares of Axsome Therapeutics in a research report on Monday. Finally, William Blair reiterated an “outperform” rating on shares of Axsome Therapeutics in a research note on Friday, January 24th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $147.13.

Axsome Therapeutics Price Performance

Axsome Therapeutics stock opened at $131.55 on Thursday. Axsome Therapeutics has a 1 year low of $64.11 and a 1 year high of $134.18. The firm’s 50-day moving average is $96.55 and its 200-day moving average is $92.67. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.37 and a current ratio of 2.44.

Hedge Funds Weigh In On Axsome Therapeutics

Large investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. lifted its stake in shares of Axsome Therapeutics by 1,815.0% in the 4th quarter. Russell Investments Group Ltd. now owns 19,437 shares of the company’s stock worth $1,645,000 after acquiring an additional 18,422 shares during the period. Envestnet Asset Management Inc. lifted its position in Axsome Therapeutics by 74.9% in the fourth quarter. Envestnet Asset Management Inc. now owns 35,129 shares of the company’s stock worth $2,972,000 after purchasing an additional 15,047 shares during the period. Pitcairn Co. lifted its position in Axsome Therapeutics by 3.4% in the fourth quarter. Pitcairn Co. now owns 4,562 shares of the company’s stock worth $386,000 after purchasing an additional 148 shares during the period. Trexquant Investment LP bought a new position in Axsome Therapeutics during the 4th quarter valued at $1,195,000. Finally, Geode Capital Management LLC increased its position in shares of Axsome Therapeutics by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 912,538 shares of the company’s stock valued at $77,228,000 after purchasing an additional 4,079 shares during the period. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.